Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “CD20+, B-cell Lymphomas”

327 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 327 results

Testing effectiveness (Phase 2)Study completedNCT03097770
What this trial is testing

Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD20

Who this might be right for
Hematopoietic/Lymphoid CancerAdult Acute Lymphoblastic Leukemia in RemissionB-cell Adult Acute Lymphoblastic Leukemia+20 more
Chinese PLA General Hospital 100
Early research (Phase 1)Active Not RecruitingNCT06824701
What this trial is testing

Tazemetostat in Combination With Zanubrutinib and Anti-CD20 Monoclonal Antibody in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Who this might be right for
Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
University of Utah 24
Testing effectiveness (Phase 2)WithdrawnNCT01138579
What this trial is testing

Study of the Trifunctional Antibody FBTA05 and Donor Lymphocyte Infusion in B-cell Lymphoma After Allogeneic Stem Cell Transplantation

Who this might be right for
LeukemiaStem Cell Transplantation
Technical University of Munich
Testing effectiveness (Phase 2)Study completedNCT00169143
What this trial is testing

Study of R-ACVBP Regimen Supported by Pegfilgrastim in High-Risk Diffuse Large B-Cell Lymphoma

Who this might be right for
Untreated CD20-positive Large B-cell Lymphoma
Lymphoma Study Association 60
Early research (Phase 1)Active Not RecruitingNCT04872790
What this trial is testing

Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia

Who this might be right for
B Acute Lymphoblastic LeukemiaB Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1Mixed Phenotype Acute Leukemia+2 more
OHSU Knight Cancer Institute 20
Testing effectiveness (Phase 2)Looking for participantsNCT05826535
What this trial is testing

Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma

Who this might be right for
Relapsed Non-Hodgkin LymphomaRefractory Non-Hodgkin LymphomaNon-Hodgkin Lymphoma+1 more
Lyell Immunopharma, Inc. 270
Testing effectiveness (Phase 2)UnknownNCT02965157
What this trial is testing

Pilot Study of Anti-CD20-CAR-engineered T Cells in Patients With Chemotherapy Resistant or Refractory CD20+ Lymphoma

Who this might be right for
Lymphoma, B-Cell
Beijing Biohealthcare Biotechnology Co.,Ltd 15
Large-scale testing (Phase 3)Study completedNCT00003150
What this trial is testing

Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Older Patients With Non-Hodgkin's Lymphoma

Who this might be right for
Lymphoma
Eastern Cooperative Oncology Group 630
Testing effectiveness (Phase 2)Study completedNCT00073918
What this trial is testing

Iodine I 131 Tositumomab, Etoposide and Cyclophosphamide Followed by Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Who this might be right for
Anaplastic Large Cell LymphomaCutaneous B-cell Non-Hodgkin LymphomaExtranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue+14 more
Fred Hutchinson Cancer Center 111
Testing effectiveness (Phase 2)UnknownNCT06503094
What this trial is testing

CD19 & CD20 Bispecific CAR T Cells for Relapsed / Refractory B Cell Hematological Tumors

Who this might be right for
B-Cell Lymphoblastic Leukemia/Lymphoma
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology 80
Early research (Phase 1)WithdrawnNCT07093086
What this trial is testing

Clinical Study of Multi-targeted CAR-T Therapy in Patients With Relapsed/Refractory B-Cell Lymphoma

Who this might be right for
B-cell Lymphoma
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
Early research (Phase 1)Looking for participantsNCT06395870
What this trial is testing

Targeting CD19/CD20 Dual-targeted Cell in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

Who this might be right for
B-Cell Non-Hodgkin Lymphoma-RecurrentB-Cell Non-Hodgkin Lymphoma-Refractory
Tianjin Medical University Cancer Institute and Hospital 33
Testing effectiveness (Phase 2)UnknownNCT02315118
What this trial is testing

Pilot Study of Autologous T Lymphocytes With ADCC in Patients With CD20-Positive B-Cell Malignancies

Who this might be right for
B-Cell Chronic Lymphocytic LeukemiaNon-Hodgkin's Lymphoma
National University Hospital, Singapore 18
Early research (Phase 1)UnknownNCT05003141
What this trial is testing

PSB202 in Patients With Previously Treated-, Relapsed-, Indolent B-Cell Malignancies

Who this might be right for
Follicular LymphomaChronic Lymphocytic Leukemia/Small Lymphocytic LymphomaWaldenstrom Macroglobulinemia+5 more
Qilu Puget Sound Biotherapeutics (dba Sound Biologics) 110
Early research (Phase 1)Study completedNCT02296918
What this trial is testing

Acalabrutinib in Combination With Anti-CD20 and Venetoclax in Relapsed/Refractory or Untreated CLL/SLL/PLL

Who this might be right for
Chronic Lymphocytic LeukemiaSmall Lymphocytic LymphomaProlymphocytic Leukemia
Acerta Pharma BV 69
Testing effectiveness (Phase 2)Active Not RecruitingNCT05950165
What this trial is testing

Assess Safety and Efficacy of CHO-H01 as a Single Agent/Combined With Lenalidomide in Subjects With Refractory or Relapsed Non-Hodgkin's Lymphoma

Who this might be right for
Non-Hodgkin Lymphoma
Cho Pharma Inc. 37
Large-scale testing (Phase 3)Study completedNCT01285765
What this trial is testing

Evaluate a Treatment Adapted to the PET Response Compared to a Standard Treatment, for Low Risk DLBCL CD 20+ Patients

Who this might be right for
DLBCL
The Lymphoma Academic Research Organisation 650
Early research (Phase 1)Study completedNCT04578600
What this trial is testing

CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma

Who this might be right for
Indolent B-Cell Non-Hodgkin LymphomaRecurrent B-Cell Non-Hodgkin LymphomaRecurrent Chronic Lymphocytic Leukemia+16 more
Joseph Tuscano 8
Early research (Phase 1)Study completedNCT04599634
What this trial is testing

Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies

Who this might be right for
Follicular LymphomaMarginal Zone LymphomaMantle Cell Lymphoma+2 more
National Cancer Institute (NCI) 11
Very early researchTemporarily pausedNCT04697290
What this trial is testing

CD19/CD20 Dual-CAR-T in B-cell Non-Hodgkin's Lymphoma Patients.

Who this might be right for
B-cell Non-Hodgkin's Lymphoma
Beijing Tsinghua Chang Gung Hospital 12
Next Page